Structured evidence table for Alpha-Gpc Memory Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Alpha-Gpc Memory Randomized Trial | Various pharmacological and nonpharmacological interventions have been introduced, but the evidence regarding their efficacy, safety, and tolerability is conflicting and inconsistent. | 1 | Sagaro Getu Gamo (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis |
| Alpha-Gpc Memory Randomized Trial | This could be attributed to a decline in the efficacy of ChE-Is treatment over time, and to the difficulty in treating specific patient categories such as older age groups, or patients with the concomitant presence of conditions such as bradycardia, bronchial asthma, or chronic obstructive pulmonary disease due to the treatment-associated adverse effects (,). | 1 | Sagaro Getu Gamo (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis |
| Alpha-Gpc Memory Randomized Trial | Studies were classified based on the quality assessment into three categories: low-risk bias (all quality criteria met), moderate-risk bias (one or more quality criteria only partly met), and high-risk bias (one or more quality criteria not met). | 1 | Sagaro Getu Gamo (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis |
| Alpha-Gpc Memory Randomized Trial | 1 2 3 4 5 6 Dementia is a condition linked to various neurodegenerative diseases, marked by a significant decline in cognitive abilities that affects daily activities (). | 1 | Sagaro Getu Gamo (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis |
| Alpha-Gpc Memory Randomized Trial | This narrative review summarizes current preclinical and clinical evidence regarding the mechanistic and clinical relevance of L-α-GPC in neurodegenerative disorders associated with cognitive impairment. | 4 | Putri VA (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. |
| Alpha-Gpc Memory Randomized Trial | In animal models, L-α-GPC has been associated with improved cognitive performance, reduced neuroinflammation, and attenuation of amyloid-β and tau-related pathological features. | 4 | Putri VA (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. |
| Alpha-Gpc Memory Randomized Trial | However, the interpretation of these findings should be cautious because the available evidence remains heterogeneous, with notable variability in study design, dosage regimens, treatment duration, and outcome measures. | 4 | Putri VA (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. |
| Alpha-Gpc Memory Randomized Trial | Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and vascular dementia are characterized by progressive neuronal loss, synaptic dysfunction, and cognitive decline. | 4 | Putri VA (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. |
Source documents